Leerink assumes coverage of Edge Therapeutics at OP

Leerink analyst Paul Mattels is assuming coverage of Edge Therapeutics (NASDAQ:EDGE) with an “outperform” rating and $21 price target. The stock closed at $9.40 on March 2.

“We view EDGE as a logical fit within our CNS focused universe,” Mr. Mattels writes. “We are assuming coverage of the stock with a positive view ahead of Phase 3 data for lead product, EG-1962, in aneurysmal subarachnoid hemorrhage in 2018 (full data expected ~3Q), with an interim analysis on track for 1Q18 as 43 sites are actively screening patients,” he added.

Citing positive Phase 2 results, conservative powering and direct CNS delivery of a proven medicine, Mr. Mattels is modeling a 65% odds of success for the Phase 3 trial, which he said is higher than average for neuroscience.

The NEWTON2 pivotal study was initiated in mid-2016 and is expected to
enroll 374 patients across approximately 80 sites worldwide. EDGE has powered NEWTON2 for a 15% treatment difference versus oral nimodipine. That implies a 43% benefit for EG-1962, which seems achievable and potentially conservative given the 32% treatment difference seen in the NEWTON Phase 2 study.

EDGE will also conduct an interim analysis when 210 patients have been treated. “Should a greater than 20% treatment difference be detected, this could potentially trigger termination of the trial, which would enable an earlier NDA filing than we currently assume,” Mr. Mattels added.


Sign up to our weekly BioTuesdays newsletter.